Research and Markets has announced the addition of the "Periodontitis - Pipeline Review, H2 2016" report to their offering.
Periodontitis pipeline therapeutics constitutes close to 15 molecules. Out of which approximately 11 molecules are developed by Companies and remaining by the Universities Institutes.
Periodontitis - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Periodontitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Periodontitis Periodontitis is a gum infection that damages the soft tissue and destroys the bone that supports teeth. Signs and symptoms of periodontitis include swollen gums, bright red or purplish gums, bad breath, bright red or purplish gums and spaces developing between teeth. Risk factors include gingivitis, heredity, diabetes, age, substance abuse and weakened immune system.
The molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 4 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.
Furthermore, this report also reviews of key players involved in therapeutic development for Periodontitis and features dormant and discontinued projects.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/j68dd5/periodontitis
View source version on businesswire.com: http://www.businesswire.com/news/home/20161004006390/en/Business Wire
Last updated on: 04/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.